Danish pharmaceutical giant Novo Nordisk is gearing up to introduce its blockbuster anti-diabetes and weight-loss drug Wegovy (semaglutide) in India. In a strategic move to gain an advantage over Eli Lilly’s newly launched Mounjaro (tirzepatide), Novo Nordisk has presented data showcasing Wegovy’s cardiovascular benefits in Indian patients, according to recent regulatory filings.
Tamil Nadu Plans Tighter Oversight of Solid Waste Contracts Across 12 Local Bodies
The Tamil Nadu government is preparing to introduce stricter monitoring mechanisms for solid waste management contracts across 12 urban local bodies, in a move aimed at improving service delivery and accountability in...





Discussion about this post